Regulatory Approval for Striate in US$65M Brazilian Market
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Orthocell Ltd has received regulatory approval from the Brazilian Health Regulatory Agency for its dental product Striate+, marking its first market authorization in Latin America. Striate+ has already gained significant traction in other markets, supported by positive feedback from dental professionals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- Remplir Cleared to Commence Sales in US$1.6B US Market
- Investor Presentation - US FDA 510(k) Clearance for Remplir
- First Sales of Striate in Germany, Austria & Swiss Region
- Regulatory approval to commence Striate sales in Singapore
- S&P DJI Announces March 2025 Quarterly Rebalance
Later from Orthocell
- First US Distributors Signed for Remplirs US$1.6B market
- Remplir Approved to Commence Sales in US$84M Thai Market
- Pause in Trading
- Replacement Trading Halt
- Remplir Approved to Commence Sales in US$75m Canadian Market
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell